{"id":84690,"date":"2026-09-10T12:28:00","date_gmt":"2026-09-10T12:28:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=84690"},"modified":"2026-09-13T00:40:31","modified_gmt":"2026-09-13T00:40:31","slug":"adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/","title":{"rendered":"Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody\u00ae Technology"},"content":{"rendered":"

Amended terms of agreement include a transition to an integrated asset and technology partnership.<\/em><\/p>\n

SAN DIEGO and SUZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced that Third Arc Bio, Inc. (\u201cThird Arc Bio\u201d) selected the first lead candidate under the amended strategic licensing agreement. The agreement was established in November 2025, under which Third Arc Bio utilizes Adagene\u2019s NEObody\u00ae and SAFEbody\u00ae technology platform to generate masked CD3 T cell engagers against unique epitopes of tumor-associated antigens. \u00a0\u00a0<\/p>\n

Under the amended terms of the agreement, the companies have broadened the scope of the collaboration. In addition to selecting the first lead candidate, Third Arc Bio will also sponsor and fund the clinical development of such program. In recognition of this broadened scope, the total potential payments (including development and commercial-based milestones) payable to Adagene under the collaboration have increased. Adagene\u00a0continues to hold a no-cost option to develop and commercialize the candidate molecules in\u00a0Greater China,\u00a0Singapore\u00a0and\u00a0South Korea.<\/p>\n

“We are pleased with the progress of this collaboration and the first lead selection. We look forward to delivering transformational therapies to patients through this highly productive partnership,” said Peter Lebowitz, M.D., Ph.D., Chief Executive Officer of Third Arc Bio.<\/p>\n

\u201cWe are proud to deepen our partnership with Third Arc Bio, a world class team with a track record of bringing innovative medicines including T cell engagers from discovery to commercialization for patients globally,\u201d said Peter Luo, Ph.D., Chairman, President of R&D and Chief Executive Officer of Adagene.<\/p>\n

About Adagene<\/strong>
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody\u00ae precision masking technology in multiple approaches at the vanguard of science.<\/p>\n

Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody, SAFEbody, and POWERbody™ technologies, Adagene\u2019s highly differentiated pipeline features novel immunotherapy programs. The company\u2019s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies, while minimizing on-target off-tumor toxicity in healthy tissues.<\/p>\n

Adagene\u2019s lead clinical program, muzastotug (ADG126), is a masked, anti-CTLA-4 SAFEbody with FDA Fast Track designation that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. Muzastotug is currently in Phase 1b\/2 and Phase 2 clinical studies in combination with anti-PD-1 therapy, particularly focused on microsatellite stable (MSS) metastatic colorectal cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi\/multi-specific T cell engagers.<\/p>\n

For more information, please visit: https:\/\/investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and X.<\/p>\n

NEObody\u00ae is a registered trademark in the United States, China, Australia, Japan, Singapore, Switzerland, Korea, United Kingdom and the European Union. SAFEbody\u00ae is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.<\/p>\n

FORWARD-LOOKING STATEMENTS<\/strong>
This press release contains forward-looking statements, including statements regarding expected clinical development plans. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene\u2019s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of the underlying drug candidates; Adagene\u2019s abil ity to achieve commercial success for its drug candidates, if approved; Adagene\u2019s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene\u2019s reliance on third parties to conduct drug development, manufacturing and other services; Adagene\u2019s limited operating history and Adagene\u2019s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene\u2019s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations and other operations, as well as those risks more fully discussed in the \u201cRisk Factors\u201d section in Adagene\u2019s filings with the\u00a0U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to\u00a0Adagene, and\u00a0Adagene\u00a0undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.<\/p>\n

Investor Contacts:<\/strong>
Raymond Tam
raymond_tam@adagene.com<\/a><\/p>\n

Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com<\/a><\/p>\n

Media Contact:<\/strong>
Ian Stone
LifeSci Communications
istone@lifescicomms.com<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced that Third Arc Bio, Inc. (\u201cThird Arc Bio\u201d) selected […]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"open","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-84690","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globe-newswire"],"yoast_head":"\nAdagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody\u00ae Technology - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody\u00ae Technology\" \/>\n<meta property=\"og:description\" content=\"Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept. 10, 2026 (GLOBE\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-10T12:28:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-13T00:40:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/09\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology.gif\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/gif\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody\u00ae Technology\",\"datePublished\":\"2026-09-10T12:28:00+00:00\",\"dateModified\":\"2026-09-13T00:40:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/\"},\"wordCount\":850,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Globe Newswire\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/\",\"name\":\"Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody\u00ae Technology - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-09-10T12:28:00+00:00\",\"dateModified\":\"2026-09-13T00:40:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody\u00ae Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody\u00ae Technology - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/","og_locale":"en_US","og_type":"article","og_title":"Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody\u00ae Technology","og_description":"Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept. 10, 2026 (GLOBE","og_url":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-09-10T12:28:00+00:00","article_modified_time":"2026-09-13T00:40:31+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/09\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology.gif","type":"image\/gif"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody\u00ae Technology","datePublished":"2026-09-10T12:28:00+00:00","dateModified":"2026-09-13T00:40:31+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/"},"wordCount":850,"commentCount":0,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Globe Newswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/","url":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/","name":"Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody\u00ae Technology - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-09-10T12:28:00+00:00","dateModified":"2026-09-13T00:40:31+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody\u00ae Technology"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/84690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=84690"}],"version-history":[{"count":1,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/84690\/revisions"}],"predecessor-version":[{"id":84692,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/84690\/revisions\/84692"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=84690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=84690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=84690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}